These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38870024)

  • 1. Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints.
    Vikelis M; Rikos D; Argyriou AA; Papachristou P; Rallis D; Karapanayiotides T; Galanopoulos A; Spingos K; Dimisianos N; Giakoumakis E; Zavridis P; Notas K; Vlachos GS; Soldatos P; Bilias K; Xiromerisiou G; Rudolf J; Dermitzakis EV; Rapoport AM
    Expert Rev Neurother; 2024 Jun; ():1-12. PubMed ID: 38870024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment.
    Bougie JK; Krupsky K; Beusterien K; Ladouceur MP; Mulvihill E
    Headache; 2024 Jul; ():. PubMed ID: 38982656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
    Schwedt TJ; Martin A; Kymes S; Talon B; Lee XY; Cady R; Asher D; Karnik-Henry M; Mulvihill E; Bates D; Beusterien K
    Headache; 2023 Apr; 63(4):484-493. PubMed ID: 36753057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' preference for migraine preventive therapy.
    Peres MF; Silberstein S; Moreira F; Corchs F; Vieira DS; Abraham N; Gebeline-Myers C
    Headache; 2007 Apr; 47(4):540-5. PubMed ID: 17445103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of outcomes and endpoints in acute migraine clinical trials.
    Houts CR; McGinley JS; Nishida TK; Buse DC; Wirth RJ; Dodick DW; Goadsby PJ; Lipton RB
    Headache; 2021 Feb; 61(2):263-275. PubMed ID: 33611818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of outcomes and endpoints in preventive migraine clinical trials.
    McGinley JS; Houts CR; Nishida TK; Buse DC; Lipton RB; Goadsby PJ; Dodick DW; Wirth RJ
    Headache; 2021 Feb; 61(2):253-262. PubMed ID: 33600610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
    Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.
    Yu S; Guo A; Wang Z; Liu J; Tan G; Yang Q; Zhang M; Yibulaiyin H; Chen H; Zhang Y; Croop R; Sun Y; Liu Y; Zhao Q; Lu Z
    J Headache Pain; 2024 Apr; 25(1):57. PubMed ID: 38627638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
    Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
    CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
    Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
    Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in Endpoints in FDA Medication Approvals: A Review of Acute and Preventive Migraine Medications.
    Sharpless LK; Kesselheim AS; Orr SL; Darrow J
    Neurology; 2023 Sep; 101(10):e989-e1000. PubMed ID: 37438124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Web-Based Survey on 2105 Greek Migraine Patients-Second Part: Efficacy of Acute and Prophylactic Migraine Treatments and Corresponding Patients' Reported Satisfaction.
    Dermitzakis EV; Kouroudi A; Argyriou AA; Spingos KC; Bilias K; Vikelis M
    Medicina (Kaunas); 2022 Dec; 59(1):. PubMed ID: 36676655
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
    Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study.
    Seo J; Smith CA; Thomas C; Tervonen T; Hareendran A; Ford JH; Stauffer VL; Nicholson RA; Duffy KH; Tockhorn-Heidenreich A
    Patient; 2022 Jan; 15(1):93-108. PubMed ID: 34131880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
    J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
    Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey.
    MacGregor EA; Brandes J; Eikermann A
    Headache; 2003 Jan; 43(1):19-26. PubMed ID: 12864754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of a Web-Based Survey on 2565 Greek Migraine Patients in 2023: Demographic Data, Imposed Burden and Satisfaction to Acute and Prophylactic Treatments in the Era of New Treatment Options.
    Dermitzakis EV; Argyriou AA; Bilias K; Barmpa E; Liapi S; Rikos D; Xiromerisiou G; Soldatos P; Vikelis M
    J Clin Med; 2024 May; 13(10):. PubMed ID: 38792309
    [No Abstract]   [Full Text] [Related]  

  • 20. A stated preference survey to explore patient preferences for novel preventive migraine treatments.
    Hubig LT; Smith T; Chua GN; Lloyd AJ; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lo SH
    Headache; 2022 Oct; 62(9):1187-1197. PubMed ID: 36047857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.